{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Intravitreal+Injection+Patients&page=2",
    "query": {
      "condition": "Intravitreal Injection Patients",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Intravitreal+Injection+Patients&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-07-23T10:09:51.788Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05643118",
      "title": "Evaluation of OLX10212 in Patients With Neovascular Age-related Macular Degeneration",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neovascular Age-related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "OLX10212 is a cell penetrating asymmetric small interference RNA (cp-asiRNA)",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "Olix Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2023-01-04",
      "completion_date": "2025-11-10",
      "has_results": false,
      "last_update_posted_date": "2025-12-11",
      "last_synced_at": "2026-07-23T10:09:51.788Z",
      "location_count": 5,
      "location_summary": "Santa Maria, California • Oak Forest, Illinois • St Louis, Missouri + 2 more",
      "locations": [
        {
          "city": "Santa Maria",
          "state": "California"
        },
        {
          "city": "Oak Forest",
          "state": "Illinois"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Troy",
          "state": "New York"
        },
        {
          "city": "Bellaire",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05643118"
    },
    {
      "nct_id": "NCT03481634",
      "title": "Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetic Macular Edema"
      ],
      "interventions": [
        {
          "name": "Brolucizumab",
          "type": "DRUG"
        },
        {
          "name": "Aflibercept",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 566,
      "start_date": "2018-07-23",
      "completion_date": "2021-10-18",
      "has_results": true,
      "last_update_posted_date": "2023-01-30",
      "last_synced_at": "2026-07-23T10:09:51.788Z",
      "location_count": 39,
      "location_summary": "Phoenix, Arizona • Beverly Hills, California • La Jolla, California + 33 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Mountain View",
          "state": "California"
        },
        {
          "city": "Santa Barbara",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03481634"
    },
    {
      "nct_id": "NCT04278417",
      "title": "Study of Efficacy and Safety of Brolucizumab Versus Panretinal Photocoagulation Laser in Patients With Proliferative Diabetic Retinopathy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Proliferative Diabetic Retinopathy"
      ],
      "interventions": [
        {
          "name": "Brolucizumab 6 mg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Panretinal photocoagulation laser",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "PROCEDURE"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 689,
      "start_date": "2020-11-19",
      "completion_date": "2024-08-19",
      "has_results": true,
      "last_update_posted_date": "2025-10-16",
      "last_synced_at": "2026-07-23T10:09:51.788Z",
      "location_count": 40,
      "location_summary": "Tucson, Arizona • Beverly Hills, California • Fullerton, California + 32 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "Redlands",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04278417"
    },
    {
      "nct_id": "NCT03059277",
      "title": "Intravitreal Alfibercept for Center Involved DME Previously Managed With Intravitreal Ranibizumab",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Diabetic Macular Edema"
      ],
      "interventions": [
        {
          "name": "Intravitreal Aflibercept",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Southeast Clinical Research Associates, LLC",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2018-06-01",
      "completion_date": "2020-09-30",
      "has_results": false,
      "last_update_posted_date": "2018-06-14",
      "last_synced_at": "2026-07-23T10:09:51.788Z",
      "location_count": 2,
      "location_summary": "Charlotte, North Carolina • Statesville, North Carolina",
      "locations": [
        {
          "city": "Charlotte",
          "state": "North Carolina"
        },
        {
          "city": "Statesville",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03059277"
    },
    {
      "nct_id": "NCT00021736",
      "title": "Phase II/III Study of Anti-VEGF in Neovascular AMD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Macular Degeneration",
        "Choroidal Neovascularization"
      ],
      "interventions": [
        {
          "name": "EYE001 anti-VEGF aptamer",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eyetech Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 540,
      "start_date": "2001-07",
      "completion_date": "2002-07",
      "has_results": false,
      "last_update_posted_date": "2005-06-24",
      "last_synced_at": "2026-07-23T10:09:51.788Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00021736"
    },
    {
      "nct_id": "NCT01027611",
      "title": "Patient Assessment of Topical Anesthetic Effectiveness for Intravitreal Injections",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pain"
      ],
      "interventions": [
        {
          "name": "proparacaine HCL 0.5%",
          "type": "DRUG"
        },
        {
          "name": "proparacaine HCL 0.5% + 4% lidocaine solution",
          "type": "DRUG"
        },
        {
          "name": "3.5% viscous lidocaine gel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Illinois Retina Associates",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 120,
      "start_date": "2009-10",
      "completion_date": "2009-12",
      "has_results": false,
      "last_update_posted_date": "2010-05-04",
      "last_synced_at": "2026-07-23T10:09:51.788Z",
      "location_count": 1,
      "location_summary": "Joliet, Illinois",
      "locations": [
        {
          "city": "Joliet",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01027611"
    },
    {
      "nct_id": "NCT03525600",
      "title": "Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Geographic Atrophy"
      ],
      "interventions": [
        {
          "name": "APL-2",
          "type": "DRUG"
        },
        {
          "name": "Sham Procedure",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Apellis Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "60 Years and older"
      },
      "enrollment_count": 621,
      "start_date": "2018-08-31",
      "completion_date": "2022-06-20",
      "has_results": true,
      "last_update_posted_date": "2023-06-18",
      "last_synced_at": "2026-07-23T10:09:51.788Z",
      "location_count": 73,
      "location_summary": "Phoenix, Arizona • Arcadia, California • Bakersfield, California + 61 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Arcadia",
          "state": "California"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03525600"
    },
    {
      "nct_id": "NCT03571100",
      "title": "Comfort and Antimicrobial Efficacy of Chlorhexidine vs Betadine for Intravitreal Injections",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Age-related Macular Degeneration",
        "Diabetic Vascular Diseases",
        "Proliferative Retinopathy",
        "Retina Vein Occlusion"
      ],
      "interventions": [
        {
          "name": "Chlorhexidine",
          "type": "DRUG"
        },
        {
          "name": "Povidine-Iodine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "MidAtlantic Retina",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2018-05-07",
      "completion_date": "2019-05-06",
      "has_results": false,
      "last_update_posted_date": "2018-06-27",
      "last_synced_at": "2026-07-23T10:09:51.788Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03571100"
    },
    {
      "nct_id": "NCT03917472",
      "title": "Efficacy and Safety of Brolucizumab vs Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetic Macular Edema"
      ],
      "interventions": [
        {
          "name": "Brolucizumab",
          "type": "DRUG"
        },
        {
          "name": "Aflibercept",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 517,
      "start_date": "2019-07-17",
      "completion_date": "2021-03-24",
      "has_results": true,
      "last_update_posted_date": "2022-08-12",
      "last_synced_at": "2026-07-23T10:09:51.788Z",
      "location_count": 74,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 66 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Campbell",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03917472"
    },
    {
      "nct_id": "NCT03295071",
      "title": "REALITY LHON Registry",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Leber Hereditary Optic Neuropathy"
      ],
      "interventions": [
        {
          "name": "Patient-reported outcomes (PROs)",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "GenSight Biologics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 44,
      "start_date": "2018-01-03",
      "completion_date": "2020-07-01",
      "has_results": false,
      "last_update_posted_date": "2026-03-02",
      "last_synced_at": "2026-07-23T10:09:51.788Z",
      "location_count": 5,
      "location_summary": "Pasadena, California • Atlanta, Georgia • Boston, Massachusetts + 2 more",
      "locations": [
        {
          "city": "Pasadena",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03295071"
    }
  ]
}